Therefore, the preconception management of patients with SLE should not only ensure sustained disease stability for at least 6 months and necessary adjustments to immunosuppressive agents, but also involve stratification of therapeutic strategies based on their history of adverse pregnancy events, thrombotic events, and the aPL profile. The gene discussed is FASLG; the disease is systemic lupus erythematosus.